- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor, Kidney Injury
- Interventions
- RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 6
- States / cities
- Duarte, California • Chicago, Illinois • New York, New York + 3 more
Recruitment Status
Active, not recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10537
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 829–840 of 10,537 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Functional Dyspepsia
- Interventions
- Transcutaneous electrical acustimulation in automatic synchronization with breathing
- Device
- Lead sponsor
- MetroHealth Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Parma, Ohio
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- TAR-200, Cetrelimab
- Drug · Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Los Angeles, California • Sherman Oaks, California + 17 more
- Conditions
- Nonsegmental Vitiligo
- Interventions
- Zasocitinib, Placebo
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Bryant, Arkansas • Fountain Valley, California • Fremont, California + 16 more
- Conditions
- Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration
- Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 4
- States / cities
- Duarte, California • Lancaster, California • South Pasadena, California + 1 more
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Irvine, California • Long Beach, California + 13 more
- Conditions
- Chronic Pain, Opioid Use Disorder, Opioid Misuse and Addiction
- Interventions
- Usual Care, Pain Self-Management
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Baltimore, Maryland • Allison Park, Pennsylvania • Blawnox, Pennsylvania + 9 more
- Conditions
- Osteoarthritis
- Interventions
- Cementless Total Knee Arthroplasty
- Device
- Lead sponsor
- DePuy Orthopaedics
- Industry
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • DeLand, Florida • Lebanon, New Hampshire + 7 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- LINX Reflux Management System
- Device
- Lead sponsor
- Ethicon Endo-Surgery
- Industry
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 18 more
- Conditions
- Hematological Malignancies
- Interventions
- Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 2 more
- Conditions
- Atopic Dermatitis
- Interventions
- APG777, Placebo
- Drug
- Lead sponsor
- Apogee Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Refractory Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Other · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California